# Ocular Therapeutix, Inc. clinical trials: 33 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Ocular Therapeutix, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ocular Therapeutix, Inc.: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ocular-therapeutix-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 7, 2026 | NCT07516132 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular... | Ocular Therapeutix, Inc. | Phase 3 | Recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516132) |
| November 19, 2025 | NCT07235085 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | Ocular Therapeutix, Inc. | Phase 3 | Recruiting | Non-Proliferative Diabetic Retinopathy | 930 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235085) |
| July 11, 2024 | NCT06495918 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular... | Ocular Therapeutix, Inc. | Phase 3 | Active not recruiting | Neovascular Age-related Macular Degeneration | 825 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06495918) |
| January 25, 2024 | NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular... | Ocular Therapeutix, Inc. | Phase 3 | Active not recruiting | Neovascular Age-Related Macular Degeneration | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06223958) |
| April 18, 2023 | NCT05814757 | OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | Ocular Therapeutix, Inc. | Phase 2 | Completed | Dry Eye Syndromes, Eye Diseases | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814757) |
| January 25, 2023 | NCT05695417 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic... | Ocular Therapeutix, Inc. | Phase 1 | Unknown | Non-proliferative Diabetic Retinopathy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05695417) |
| April 19, 2022 | NCT05335122 | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or... | Ocular Therapeutix, Inc. | Phase 2 | Completed | Open Angle Glaucoma, Ocular Hypertension | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05335122) |
| April 1, 2022 | NCT05307081 | An Observational, Qualitative Study Assessing Eye Drop Administration | Ocular Therapeutix, Inc. | Observational | Unknown | Ocular Injury | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05307081) |
| August 4, 2021 | NCT04989699 | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration | Ocular Therapeutix, Inc. | Phase 1 | Completed | Neovascular Age-Related Macular Degeneration | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04989699) |
| June 30, 2021 | NCT04945824 | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects | Ocular Therapeutix, Inc. | Early phase 1 | Terminated | Healthy | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04945824) |
| February 10, 2021 | NCT04747977 | To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease | Ocular Therapeutix, Inc. | Phase 2 | Completed | Dry Eye | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04747977) |
| September 7, 2020 | NCT04539548 | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric... | Ocular Therapeutix, Inc. | Phase 3 | Completed | Cataract | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04539548) |
| April 27, 2020 | NCT04362670 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. | Ocular Therapeutix, Inc. | Phase 1/2 | Completed | Dry Eye Disease | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04362670) |
| April 24, 2020 | NCT04360174 | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension | Ocular Therapeutix, Inc. | Phase 1 | Completed | Ocular Hypertension, Open Angle Glaucoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04360174) |
| August 19, 2019 | NCT04061044 | A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert | Ocular Therapeutix, Inc. | Phase 3 | Completed | Open Angle Glaucoma and Ocular Hypertension | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04061044) |
| August 8, 2019 | NCT04050865 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis | Ocular Therapeutix, Inc. | Phase 3 | Completed | Allergic Conjunctivitis | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04050865) |
| August 14, 2018 | NCT03630315 | CLN-0046: Treatment of AMD Subjects With OTX-TKI | Ocular Therapeutix, Inc. | Phase 1 | Completed | Neovascular Age-related Macular Degeneration | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03630315) |
| December 9, 2016 | NCT02988882 | OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | Ocular Therapeutix, Inc. | Phase 3 | Completed | Chronic Allergic Conjunctivitis | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02988882) |
| September 26, 2016 | NCT02914509 | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT | Ocular Therapeutix, Inc. | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 565 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02914509) |
| April 13, 2016 | NCT02736175 | OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract... | Ocular Therapeutix, Inc. | Phase 3 | Completed | Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation | 438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02736175) |
| June 11, 2015 | NCT02468700 | OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye | Ocular Therapeutix, Inc. | Phase 2 | Completed | Dry Eye | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02468700) |
| May 15, 2015 | NCT02445326 | OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | Ocular Therapeutix, Inc. | Phase 3 | Completed | Chronic Allergic Conjunctivitis | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02445326) |
| December 9, 2014 | NCT02312544 | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or... | Ocular Therapeutix, Inc. | Phase 2 | Completed | Glaucoma, Ocular Hypertension | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02312544) |
| December 8, 2014 | NCT02310815 | ReSure Sealant Post Approval Study | Ocular Therapeutix, Inc. | Observational | Completed | Adverse Events | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02310815) |
| December 5, 2014 | NCT02309736 | OTX-14-002: Device Exposure Registry | Ocular Therapeutix, Inc. | Observational | Withdrawn | Endophthalmitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02309736) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 3 | 14 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Unknown | 3 |
| Active not recruiting | 2 |
| Recruiting | 2 |
| Terminated | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ocular Hypertension | 5 |
| Dry Eye Syndromes | 4 |
| Glaucoma, Open-Angle | 4 |
| Pain | 2 |
| Cataract | 2 |
| Glaucoma | 2 |
| Eye Injuries | 1 |
| Conjunctivitis, Allergic | 1 |
| Endophthalmitis | 1 |
| Eye Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
